ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets
Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
Listed drug development sector has several promising stories to tell this year
It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...